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Abstract LKB1 is a serine-threonine protein kinase mutated in
patients with an autosomal dominantly inherited cancer syn-
drome predisposing to multiple benign and malignant tumours,
termed Peutz^Jeghers syndrome. Since its discovery in 1998,
much research has focused on identi¢cation and characterisation
of its cellular roles and analysing how LKB1 might be regulated.
In this review we discuss exciting recent advances indicating
that LKB1 functions as a tumour suppressor perhaps by con-
trolling cell polarity. We also outline the current understanding
of the molecular mechanisms by which LKB1 is regulated in
vivo, through interaction with other proteins as well as by pro-
tein phosphorylation and prenylation.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Peutz^Jeghers syndrome (PJS) was ¢rst described in 1922
by a Dutch physician, Dr Johannes Peutz [1], and further
characterised in the 1940s by Dr Harold Jeghers [2,3]. It is
an autosomal dominantly inherited disorder exempli¢ed by
patients developing multiple hamartomatous polyps (benign
overgrowth of di¡erentiated tissues) in the gastrointestinal
tract as well as pigmentation of the mucous membranes.
PJS patients also have a markedly increased risk of developing
malignant tumours mostly in the intestine, stomach and pan-
creas but also in other tissues including breast, cervix, lung,
ovary, testis and uterus [4^6]. It is estimated that 93% of PJS
patients will develop malignant tumour(s) at an average age of
43 years [7]. The reported estimates of the incidence frequency
of PJS vary signi¢cantly. One report estimated the frequency
to be 1:8300 live births [8], while another study put the esti-
mate at 1:120 000 [4]. In the UK, there are estimated to be
around 2000 people with PJS, indicating the incidence fre-
quency is 1:30 000 (Association of International Cancer
Research, http://www.aicr.org.uk/cancer_syndromes.htm). Al-
though the majority of PJS patients have a family history of
this condition, 10^20% of the cases are apparently caused by
de novo LKB1 germline mutations [9].
In 1997, linkage analysis of multiple hamartomas derived
from PJS patients suggested that the causative locus for this
disorder was located at chromosome 19p13.3 [10]. In 1998,
two groups reported that the gene mutated in PJS families
was a previously uncharacterised serine-threonine protein ki-
nase, termed LKB1 [11] or STK11 [12]. The LKB1 nomencla-
ture is now normally employed and arose as a code name for
the PJS causative gene. The LKB1 gene spans 23 kb and is
composed of 10 exons, nine of which are coding, and the gene
is transcribed in the telomere to centromere direction [12]. The
human LKB1 protein kinase comprises 433 residues (436 ami-
no acids for mouse LKB1), and its catalytic domain (residues
44^309) is poorly related to other protein kinases. The
N-terminal and C-terminal non-catalytic regions of LKB1
are not related to any other proteins and possess no identi¢-
able functional domains. LKB1 is ubiquitously expressed in
all foetal and adult tissues examined [11,12]. To date, 75 mu-
tations in LKB1 have been identi¢ed to our knowledge in PJS
patients, and the types of mutations found are summarised in
Fig. 1. The majority of these mutations would be expected to
impair LKB1 catalytic activity, but a number of mutations
only a¡ect the C-terminal non-catalytic region (Fig. 1). Pa-
tients with sporadic cancers have also been screened for mu-
tations in the LKB1 gene, and although their frequency is
relatively rare, 24 mutations have been identi¢ed, which are
listed in Fig. 1. Recently, it has been suggested that sporadic
mutations in LKB1 are found in one third of lung adenocar-
cinomas [13].
2. Overexpression studies
An important early ¢nding was that overexpression of wild
type LKB1 in two cancer cell lines (HeLa and G361) which do
not express endogenous LKB1, suppressed the growth of
these cells by inducing a G1 cell cycle arrest [14]. Catalytically
inactive LKB1 mutants including some of those isolated from
PJS patients failed to suppress cell growth. This was the ¢rst
indication that LKB1 functioned as a tumour suppressor and
that serine-threonine protein kinase catalytic activity was re-
quired for this function. One study indicated that overexpres-
sion of LKB1 in G361 melanoma cells induced the expression
of the p21WAF1=CIP1 inhibitor of the cyclin-dependent kinases,
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Fig. 1. Mutations identi¢ed in the LKB1 gene in patients with PJS and sporadic cancer and schematic representation of their predicted e¡ects
on the primary structure of LKB1; Refs. [9,11^13,50^70]. Unless otherwise marked, the mutations are derived from PJS patients. The muta-
tions marked with symbols are derived as follows: * colorectal cancer, # lung cancer, 2 pancreatic cancer, 3 melanoma cancer, V testicular can-
cer, 4 ovarian cancer, b gastric carcinoma, w cervical cancer. Abbreviations: fs, frameshift; NRD, N-terminal Regulatory Domain; CRD, C-ter-
minal Regulatory Domain.
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which could account for the ability of LKB1 to induce a G1
cell cycle arrest [15]. In another study, microarray analysis
revealed that overexpression of LKB1 in A549 cells induced
expression of several p53 responsive genes, implicating the p53
pathway being controlled by LKB1 [16]. Overexpression of
LKB1 in A549 cells also resulted in a signi¢cant increase in
the tumour suppressor PTEN mRNA expression. PTEN func-
tions as a lipid phosphatase metabolising the phosphatidylino-
sitol 3,4,5-trisphosphate (PIP3) second messenger which con-
trols proliferation and survival of cells [17]. Thus, lack of
LKB1 could result in reduced expression of PTEN, thereby
increasing PIP3 levels and enhancing proliferation and surviv-
al of these cells [16]. Interestingly, PTEN is also mutated in an
autosomal dominantly inherited cancer disease termed Cow-
den’s syndrome, which is phenotypically similar to PJS [18],
further suggesting a link between PTEN and LKB1. In future
work it would be important to study the levels of PTEN and
PIP3 in tumours from PJS patients.
Much work has also focused on analysing the cellular local-
isation of LKB1, mainly employing overexpression ap-
proaches. These studies revealed that LKB1 was mainly local-
ised in the nucleus, although a small fraction was reproducibly
found in the cytoplasm [15,19,20]. LKB1 possesses a nuclear
localisation signal at its N-terminal non-catalytic region (res-
idues 38^43) and mutation of this motif results in LKB1 being
located throughout the cell [19,21]. Interestingly, a mutant of
LKB1 lacking the nuclear localisation signal still retains abil-
ity to suppress cell growth [15], suggesting that the cytosolic
pool of LKB1 may play an important role in mediating its
tumour suppressor properties. In addition, at least one mutant
of LKB1 isolated from a PJS patient, termed SL26, which
lacks three amino acids at the C-terminus of the kinase do-
main, still retains normal in vitro catalytic activity, but is
unable to suppress cell growth and localises exclusively in
the cell nucleus [15]. This further suggests that cytosolic loca-
tion of LKB1 is important for its cell growth suppression
properties.
3. Mouse knockouts
Several groups have reported that targetted disruption of
both LKB1 alleles leads to embryonic lethality at midgesta-
tion, indicating that LKB1 plays an important role in embryo-
genesis [22^24]. LKB13=3 embryos displayed no apparent ab-
normalities until E8.0. Beyond E8.25, the embryos revealed
multiple irregularities, including failure of the embryo to turn,
a defect in neural tube closure, abnormal development of the
aorta and hypoplastic ¢rst branchial arch. No viable
LKB13=3 embryos were found after E11.0. Extraembryonic
development was also severely a¡ected in LKB13=3 embryos,
with the placenta displaying defective labyrinth layer develop-
ment and the foetal vessels failing to invade the placenta [22].
Vascular endothelial growth factor (VEGF) mRNA levels in
LKB13=3 embryos at E8.5 and E9.5 were observed to be
elevated, and primary mouse embryonic ¢broblasts derived
from LKB13=3 embryos at E8.5 displayed abnormally high
basal and hypoxia-induced levels of VEGF mRNA, indicating
that LKB1 might regulate VEGF production and vascular
development [22]. Interestingly, the Xenopus counterpart of
LKB1, termed XEEK1, is also highly expressed in oocytes,
eggs and early embryos, further suggesting a role of LKB1 in
embryogenesis [25].
LKB1þ=3 heterozygous mice were viable and displayed no
obvious phenotype at birth and early adult life. However, by
the age of 45 weeks most LKB1þ=3 animals developed polyps
in the gastrointestinal tract, predominantly in the glandular
stomach. Histologically, these hamartomatous polyps were
similar to those found in PJS patients [23,24,26,27]. It should
be noted, however, that the location of polyp development in
LKB1þ=3 mice, predominantly in glandular stomach, was dis-
tinct from that of PJS patients, who develop polyps mainly in
the small intestine. Di¡erences in preferential sites for intesti-
nal tumour formation in mice and humans have also been
observed with adenomatous polyposis coli knockout mice
[28].
A major question concerning the mechanism of tumour
formation in the LKB1þ=3 animals was whether gastrointes-
tinal polyps still expressed LKB1. Unfortunately the results
obtained from such studies have yielded con£icting conclu-
sions. Three groups, who analysed a total of 10 polyps for
LKB1 mRNA expression and eight polyps for LKB1 protein
expression, reported that the levels were similar to those seen
in normal mucosa cells taken from LKB1þ=3 mice and were
roughly half the amount compared to that observed in the
wild type (LKB1þ=þ) gastric mucosa or glandular stomach
cells [23,24,26]. No LKB1 mutations were identi¢ed in any
of the polyps analysed from LKB1þ=3 mice. These results
suggested that haploinsu⁄ciency in LKB1þ=3 animals is suf-
¢cient to induce polyposis [23,24,26]. However, a fourth study
reported that three out of 12 polyps isolated from LKB1þ=3
mice showed loss of the wild type LKB1 allele [27]. Moreover,
the LKB1 protein was not detected in four out of eight polyps
from LKB1þ=3 mice that retained a wild type LKB1 allele,
suggesting epigenetic gene inactivation had occurred [27].
Thus, these results suggest that the loss of LKB1 expression
is required to induce polyp formation.
The incidence of intestinal or extraintestinal cancers has not
been reported in the majority of LKB1þ=3 mice, possibly
because the mice die before the onset of carcinomas and meta-
stasis, as a result of intestinal obstruction and/or bleeding
from polyps [24]. However, a recent report indicated that a
signi¢cant number of LKB1þ=3 mice over the age of 50 weeks
developed hepatocellular carcinoma [29]. Interestingly, no ex-
pression of LKB1 mRNA and protein was observed in these
hepatocellular carcinomas, indicating that complete loss of
LKB1 expression is required for the development of carcino-
mas [29].
Molecular analysis of the polyps from LKB1þ=3 mice also
revealed that the levels of cyclooxygenase-2 (COX-2) protein
were signi¢cantly increased [26]. Induction of COX-2 is im-
plicated in promotion of tumour formation and progression
[30]. A marked increase in the levels of activated extracellular
regulated kinase (ERK) 1/ERK2 was also noted in the polyps
of LKB1þ=3 mice, which could be responsible for inducing
elevated COX-2 levels, as the expression of this gene is known
to be regulated by ERK1/ERK2 [26]. However, the mecha-
nism by which LKB1 could regulate ERK1/ERK2 and/or
COX-2 expression has not been investigated.
4. Role of LKB1 in cell polarity
Putative counterparts of mammalian LKB1 have been re-
ported in Caenorhabditis elegans [31] and Drosophila [32]. The
C. elegans homologue, termed PAR-4, has 42% amino acid
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identity within the kinase domain to human LKB1 but only
displays 26% overall identity to the human LKB1 protein, as
the non-catalytic regions of these proteins are poorly con-
served. PAR-4 was identi¢ed as a member of the maternally
expressed PAR (partitioning defective) gene family, which are
required for establishing cell polarity during the ¢rst cycle of
C. elegans embryogenesis, determining the subsequent devel-
opmental fates of the daughter cells [33]. Maternal e¡ect lethal
mutations in PAR-4 have been shown to a¡ect several aspects
of cell polarity [34]. Interestingly, mutations in the PAR-4
gene lead to similar phenotypes as mutations in the PAR-1
gene, which also encodes a serine-threonine kinase [35]. This
suggests that PAR-1 and PAR-4 could function on the same
signalling network. Recent ¢ndings suggest that the Drosophi-
la homologue of human LKB1, which possesses 44% overall
identity to human LKB1, with 66% identity within the kinase
domain, also regulates cell polarity, as it is required for estab-
lishing the polarity of the anterior^posterior embryonic axis
[32]. As observed in C. elegans, Drosophila PAR-1 and LKB1
mutants also display similar phenotypes [36,37]. Moreover,
Drosophila LKB1 can suppress the polarity phenotype of
PAR-1 mutants when overexpressed, suggesting that Droso-
phila LKB1 functions downstream of PAR-1 [32]. Consistent
with this notion, Drosophila LKB1 was shown to be phos-
phorylated by PAR-1 [32]. The ¢nding that LKB1 regulates
cell polarity is important as it suggests that hamartoma for-
mation in PJS patients could result in inappropriate over-
growths of di¡erentiated cells, which have lost their ability
to regulate their polarity as a consequence of LKB1 inactiva-
tion.
5. Posttranslational modi¢cations
It has been reported that eight residues on LKB1 are phos-
phorylated (Fig. 2). Ser31, Ser325, Thr366 and Ser431 are
phosphorylated by distinct upstream kinases whereas
Thr185, Thr189, Thr336 and Thr402 comprise autophosphor-
ylation sites. It should be noted that Thr185 and Thr402 sites
were mapped in human LKB1 [38], whereas the other residues
were mapped in mouse LKB1 [21,39] (Fig. 2). Mutation of
any of these sites of phosphorylation, either to Ala to abolish
phosphorylation or to Glu to mimic phosphorylation, had no
e¡ect on LKB1 in vitro catalytic activity or its in vivo cellular
localisation [21,39]. Mutation of Ser431 to either Ala or Glu
prevented LKB1 from suppressing the growth of G361 cells in
a colony formation assay, suggesting that phosphorylation of
this residue is essential for LKB1 to inhibit cell growth [39].
Mutation of Thr336, the major autophosphorylation site on
LKB1, to Glu but not Ala prevented LKB1 from inhibiting
G361 cell growth, suggesting that phosphorylation of this res-
idue may inhibit LKB1 tumour suppressor function [21]. In
contrast, mutation of Ser31, Ser325 or Thr366 had no major
e¡ect on the ability of LKB1 to suppress G361 cell growth
[21].
The Thr336, Thr366 and Ser431 phosphorylation sites and
the residues surrounding these are highly conserved in Droso-
phila, Xenopus and mammalian LKB1 but not in C. elegans
LKB1 (Fig. 2). Genetic and pharmacological evidence
strongly indicates that endogenously expressed LKB1 is phos-
phorylated at Ser431 by the p90 ribosomal S6 protein kinase
(RSK) and the cyclic AMP-activated protein kinase (PKA), in
Fig. 2. Location of the phosphorylation and prenylation sites on mouse LKB1. The identity of the upstream protein kinases phosphorylating
LKB1 is indicated. It should be noted that it is controversial whether Thr189 represents a site of autophosphorylation [21]. The Ser31, Thr185
and Thr189, Ser325 and Ser336 are identical in number in human and mouse LKB1. In human LKB1 Thr366 is Thr363, Ser404 is Thr402,
Ser431 is Ser428 and Cys433 is Cys430. NLS is nuclear localisation signal.
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response to agonists which trigger the activation of these ki-
nases [39,40]. Therefore, RSK and PKA may regulate cell
growth through phosphorylation of LKB1. Phosphorylation
of LKB1 at Thr366 is triggered only following exposure of
cells to ionising radiation, and it is likely that the DNA dam-
age-activated ataxia-telangiectasia mutated (ATM) kinase me-
diates this phosphorylation in vivo [41]. This latter observa-
tion provides the ¢rst evidence that LKB1 may be controlled
by ATM and could thus play a role in mediating DNA dam-
age responses in cells. The upstream kinases phosphorylating
LKB1 at Ser31 and Ser325 have not yet been characterised.
Collins et al. [40] were the ¢rst to notice that mammalian
LKB1 terminated in the amino acid sequence Cys-Lys-Gln-
Gln, which lies in the consensus sequence for protein preny-
lation [42,43]. This motif is conserved in LKB1 homologues in
Xenopus, Drosophila but not C. elegans. LKB1 expressed in
293 cells was shown to be prenylated by labelling with
[14C]mevalonic acid, and mutation of the Cys residue in the
prenylation motif (Cys433) abolished prenylation [39,40].
Mass spectrometry analysis revealed that the form of preny-
lation on LKB1 was farnesylation rather than geranylgerany-
lation [39]. Recent genetic analysis in Drosophila indicated
that both phosphorylation of the Ser431 residue by PKA
and the prenylation of Cys433 are essential for LKB1 to reg-
ulate cell polarity [32]. However, the mechanism by which
prenylation controls LKB1 is unclear, as the LKB1[C433A]
mutant possessed normal in vitro catalytic activity, was able
to suppress G361 cell growth [39] and displayed indistinguish-
able cellular localisation to wild type LKB1 [21]. Cys433 is
located two residues away from Ser431, the site of RSK and
PKA modi¢cation, but mutation of Ser431 to either Ala or
Glu did not a¡ect farnesylation of Cys433 and mutation of
Cys433 to Ala also had no e¡ect on phosphorylation of LKB1
at Ser431 in response to agonists that activate RSK and PKA
[39].
6. LKB1 interacting proteins
In order to elucidate the mechanisms by which LKB1 func-
tions in cells or is regulated in vivo, many groups have fo-
cussed on identifying proteins that interact with LKB1, and
numerous proteins have been reported to bind this enzyme.
The LKB1 interacting protein-1 (LIP1) was identi¢ed in a
yeast two hybrid screen of a mouse embryonic cDNA library,
using mouse LKB1 as the bait [44], and this interaction was
also con¢rmed in mammalian cells using coimmunoprecipita-
tion experiments. LIP1 is not a substrate of LKB1, but in-
stead was proposed to anchor LKB1 to the cytoplasm [44].
LKB1 was also reported to interact with the Brahma-related
gene-1 protein (Brg1), a member of the SWI1^SNF2 complex.
Brg1 possesses an ATP-dependent helicase activity that is nec-
essary for the chromatin remodelling function of the SWI1^
SNF2 complex and is required for the transcription of many
genes [45]. The N-terminal region of LKB1 (residues 1^146)
mediated the binding to the helicase domain of Brg1.
Although Brg1 was not phosphorylated by LKB1, the in vitro
Brg1 ATPase activity was increased by binding to LKB1, and
Brg1-induced cell cycle arrest was reported to require LKB1
[45]. LKB1 is highly expressed in apoptotic epithelial cells
which express the tumour suppressor p53 and LKB1 was
found to be coimmunoprecipitated with p53 from ¢brosarco-
ma HT1080 cell lysates, suggesting that LKB1 physically as-
sociated with p53 or its associated proteins [46]. Furthermore,
it was shown that overexpression of LKB1 in HT1080 cells
induced apoptosis in a p53-dependent manner and that LKB1
kinase activity was required for this. In apoptotic cells, LKB1
was also suggested to translocate to mitochondria, and over-
expression of a catalytically inactive mutant of LKB1 inhib-
ited apoptosis induced by agents that disrupt microtubules but
not by compounds that induce DNA damage. Based on these
observations, it was suggested that LKB1 might function as a
sensor for microtubule integrity [46]. Endogenous LKB1 im-
munoprecipitated from a variety of mammalian cell lines was
also found to be complexed with heat shock protein 90
(Hsp90) and the Cdc37 kinase speci¢c targetting subunit for
Hsp90 [47]. As is the case for other protein kinases complexed
to Cdc37 and Hsp90, such as the Raf and IKK protein ki-
nases, the kinase domain of LKB1 mediated the interaction
with this chaperone complex. Treatment of cells with Hsp90
inhibitors induced the degradation of cellular LKB1, which
was prevented by proteasome inhibitors, suggesting that the
binding of LKB1 to Cdc37 and Hsp90 is required for the
stabilisation of LKB1 [47]. Hsp90 inhibitors are being consid-
ered as antitumour agents but the ¢nding that these will de-
stabilise LKB1 suggests that such compounds could also have
the potential to induce tumours. Human and Drosophila
LKB1 have also been found to interact with and phosphory-
late the activator of G protein signalling-3 protein. It has been
proposed that through this mechanism, LKB1 could modulate
G protein coupled signalling pathways as well as potentially
impinging on pathways that a¡ect cell polarity [48].
Recently endogenous LKB1 was discovered to interact
through its catalytic domain with a novel STE20-related pro-
tein termed STRADK [38]. STRADK possesses a STE20-like
protein kinase domain, but lacks two key motifs in subdo-
mains VIb and VII of its catalytic domain, indispensable for
catalytic activity. This explains why STRADK is catalytically
inactive and has therefore been classi¢ed as a pseudokinase.
Interestingly, binding of STRADK to LKB1 enhanced LKB1
in vitro activity about ¢ve-fold [38]. Moreover, STRADK is
directly phosphorylated by LKB1 both in vitro and in vivo.
The LKB1 phosphorylation sites on STRADK have been
mapped to Thr329 and Thr419 but the role that this phos-
phorylation plays in regulating LKB1 function is unknown
[38]. STRADK, like LIP1, also functions to anchor LKB1 in
the cytoplasm. Importantly, the SL26 LKB1 mutant was
found to be incapable of binding to STRADK, which might
account for the exclusive nuclear localisation and inability of
this mutant to suppress cell growth [38]. The importance of
binding of STRADK to LKB1 was also demonstrated by the
¢nding that RNAi depletion of STRADK in G361 cells inhib-
ited LKB1 from inducing a G1 cell cycle arrest [38].
7. Conclusions and perspective
Five years have now elapsed since LKB1 was originally
identi¢ed. Although considerable progress has been made
mainly from genetic analysis in humans, mice, and model
organisms, indicating that LKB1 regulates cell proliferation
and polarity, we still only have a limited understanding of
the detailed molecular mechanism by which these e¡ects are
mediated. A major challenge for future research will be to
identify the cellular substrates which LKB1 phosphorylates,
and identify how phosphorylation of these provoke the e¡ects
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that LKB1 has on cell polarity and proliferation. This is likely
to provide signi¢cant new insights into the intrinsic cellular
mechanisms that control growth and polarity. LKB1 is un-
likely to represent a drug target itself, as many tumours lack
expression of LKB1, and moreover, drugs that inhibited
LKB1 would be expected to induce tumours. However, if
substrates of LKB1 could be identi¢ed which were enzymes,
then drugs that mimicked the e¡ect of LKB1 on these could
potentially inhibit cell growth. Such compounds might not
only be useful for the treatment of PJS but might also be
employed for inhibiting the growth of other types of cancers.
Further investigation is also required to understand how
LKB1 is regulated by interaction with other proteins and by
protein phosphorylation and prenylation. It should be noted
that many of the sites of phosphorylation and prenylation are
located in the C-terminal non-catalytic region of LKB1 (Fig.
2), and numerous mutations that a¡ect only this region of
LKB1 have been identi¢ed in tumours (Fig. 1). Thus, the
C-terminal region of LKB1 is likely to play important roles,
although these have yet to be de¢ned. Apparently, a small but
nevertheless signi¢cant number of inherited forms of PJS
found in certain families do not exhibit mutations in the
LKB1 gene [49,50], indicating that there could be other caus-
ative loci for PJS. Identifying these genes is of crucial impor-
tance as these are likely to lie in the same signalling network
as LKB1. Although genetic analysis to date has excluded that
LIP1 is mutated in these PJS patients [49], it would be very
interesting to verify whether mutations in the genes encoding
STRADK or any of the upstream kinases that phosphorylate
LKB1 could result in PJS.
Acknowledgements: Our work is supported by the Association for
International Cancer Research, Diabetes UK, the Medical Research
Council and the pharmaceutical companies that support the Division
of Signal Transduction Therapy (AstraZeneca, Boehringer-Ingelheim,
GlaxoSmithKline, Novo-Nordisk and P¢zer).
References
[1] Peutz, J.L.A. (1921) Ned. Maandschr. Geneesk. 10, 134^146.
[2] Jeghers, H. (1944) New Engl. J. Med. 231, 122^129.
[3] Jeghers, H., McKusick, V.A. and Katz, K.H. (1949) New Engl. J.
Med. 241, 992^1005.
[4] Hemminki, A. (1999) Cell Mol. Life Sci. 55, 735^750.
[5] Tomlinson, I.P. and Houlston, R.S. (1997) J. Med. Genet. 34,
1007^1011.
[6] Westerman, A.M. et al. (1999) Lancet 353, 1211^1215.
[7] Giardiello, F.M., Brensinger, J.D., Tersmette, A.C., Goodman,
S.N., Petersen, G.M., Booker, S.V., Cruz-Correa, M. and O¡er-
haus, J.A. (2000) Gastroenterology 119, 1447^1453.
[8] Mallory, S.B. and Stough, D.B.T. (1987) Dermatol. Clin. 5, 221^
230.
[9] Boardman, L.A. et al. (2000) Hum. Mutat. 16, 23^30.
[10] Hemminki, A. et al. (1997) Nat. Genet. 15, 87^90.
[11] Hemminki, A. et al. (1998) Nature 391, 184^187.
[12] Jenne, D.E. et al. (1998) Nat. Genet. 18, 38^43.
[13] Sanchez-Cespedes, M. et al. (2002) Cancer Res. 62, 3659^3662.
[14] Tiainen, M., Ylikorkala, A. and Makela, T.P. (1999) Proc. Natl.
Acad. Sci. USA 96, 9248^9251.
[15] Tiainen, M., Vaahtomeri, K., Ylikorkala, A. and Makela, T.P.
(2002) Hum. Mol. Genet. 11, 1497^1504.
[16] Jimenez, A.I., Fernandez, P., Dominguez, O., Dopazo, A. and
Sanchez-Cespedes, M. (2003) Cancer Res. 63, 1382^1388.
[17] Cantley, L.C. (2002) Science 296, 1655^1657.
[18] Liaw, D. et al. (1997) Nat. Genet. 16, 64^67.
[19] Smith, C.M., Radzio-Andzelm, E., Madhusudan, Akamine, P.
and Taylor, S.S. (1999) Prog. Biophys. Mol. Biol. 71, 313^341.
[20] Nezu, J., Oku, A. and Shimane, M. (1999) Biochem. Biophys.
Res. Commun. 261, 750^755.
[21] Sapkota, G.P., Boudeau, J., Deak, M., Kieloch, A., Morrice, N.
and Alessi, D.R. (2002) Biochem. J. 362, 481^490.
[22] Ylikorkala, A., Rossi, D.J., Korsisaari, N., Luukko, K., Alitalo,
K., Henkemeyer, M. and Makela, T.P. (2001) Science 293, 1323^
1326.
[23] Miyoshi, H., Nakau, M., Ishikawa, T.O., Seldin, M.F., Oshima,
M. and Taketo, M.M. (2002) Cancer Res. 62, 2261^2266.
[24] Jishage, K.I. et al. (2002) Proc. Natl. Acad. Sci. USA 99, 8903^
8908.
[25] Su, J.Y., Erikson, E. and Maller, J.L. (1996) J. Biol. Chem. 271,
14430^14437.
[26] Rossi, D.J. et al. (2002) Proc. Natl. Acad. Sci. USA 99, 12327^
12332.
[27] Bardeesy, N. et al. (2002) Nature 419, 162^167.
[28] Shibata, H. et al. (1997) Science 278, 120^123.
[29] Nakau, M., Miyoshi, H., Seldin, M.F., Imamura, M., Oshima,
M. and Taketo, M.M. (2002) Cancer Res. 62, 4549^4553.
[30] Dempke, W., Rie, C., Grothey, A. and Schmoll, H.J. (2001)
J. Cancer Res. Clin. Oncol. 127, 411^417.
[31] Watts, J.L., Morton, D.G., Bestman, J. and Kemphues, K.J.
(2000) Development 127, 1467^1475.
[32] Martin, S.G. and St Johnston, D. (2003) Nature 421, 379^384.
[33] Kemphues, K.J., Priess, J.R., Morton, D.G. and Cheng, N.S.
(1988) Cell 52, 311^320.
[34] Morton, D.G., Roos, J.M. and Kemphues, K.J. (1992) Genetics
130, 771^790.
[35] Guo, S. and Kemphues, K.J. (1995) Cell 81, 611^620.
[36] Shulman, J.M., Benton, R. and St Johnston, D. (2000) Cell 101,
377^388.
[37] Tomancak, P., Piano, F., Riechmann, V., Gunsalus, K.C.,
Kemphues, K.J. and Ephrussi, A. (2000) Nat. Cell Biol. 2,
458^460.
[38] Baas, A.F., Boudeau, J., Sapkota, G.P., Smit, L., Medema, R.,
Morrice, N.A., Alessi, D.R. and Clevers, H.C. (2003) EMBO J.
(in press).
[39] Sapkota, G.P. et al. (2001) J. Biol. Chem. 276, 19469^19482.
[40] Collins, S.P., Reoma, J.L., Gamm, D.M. and Uhler, M.D. (2000)
Biochem. J. 345, 673^680.
[41] Sapkota, G.P. et al. (2002) Biochem. J. 368, 507^516.
[42] Moores, S.L. et al. (1991) J. Biol. Chem. 266, 14603^14610.
[43] Zhang, F.L. and Casey, P.J. (1996) Annu. Rev. Biochem. 65,
241^269.
[44] Smith, D.P., Rayter, S.I., Niederlander, C., Spicer, J., Jones,
C.M. and Ashworth, A. (2001) Hum. Mol. Genet. 10, 2869^2877.
[45] Marignani, P.A., Kanai, F. and Carpenter, C.L. (2001) J. Biol.
Chem. 276, 32415^32418.
[46] Karuman, P. et al. (2001) Mol. Cell 7, 1307^1319.
[47] Boudeau, J., Deak, M., Lawlor, M.A., Morrice, N.A. and Alessi,
D.R. (2003) Biochem. J. 370, 849^857.
[48] Blumer, J.B., Bernard, M.L., Peterson, Y.K., Nezu, J., Chung,
P., Dunican, D.J., Knoblich, J.A. and Lanier, S.M. (2003) J. Biol.
Chem. (in press).
[49] Buchet-Poyau, K., Mehenni, H., Radhakrishna, U. and Antona-
rakis, S.E. (2002) Cytogenet. Genome Res. 97, 171^178.
[50] Resta, N. et al. (2002) Hum. Mutat. 20, 78^79.
[51] Rowan, A., Bataille, V., MacKie, R., Healy, E., Bicknell, D.,
Bodmer, W. and Tomlinson, I. (1999) J. Invest. Dermatol. 112,
509^511.
[52] Olschwang, S., Boisson, C. and Thomas, G. (2001) J. Med. Ge-
net. 38, 356^360.
[53] Westerman, A.M. et al. (1999) Hum. Mutat. 13, 476^481.
[54] Wang, Z.J. et al. (1999) J. Med. Genet. 36, 365^368.
[55] Ylikorkala, A. et al. (1999) Hum. Mol. Genet. 8, 45^51.
[56] Avizienyte, E. et al. (1998) Cancer Res. 58, 2087^2090.
[57] Dong, S.M. et al. (1998) Cancer Res. 58, 3787^3790.
[58] Mehenni, H. et al. (1998) Am. J. Hum. Genet. 63, 1641^1650.
[59] Avizienyte, E. et al. (1999) Am. J. Pathol. 154, 677^681.
[60] Guldberg, P., thor Straten, P., Ahrenkiel, V., Seremet, T., Kirkin,
A.F. and Zeuthen, J. (1999) Oncogene 18, 1777^1780.
[61] Yoon, K.A. et al. (2000) Br. J. Cancer 82, 1403^1406.
[62] Scott, R.J., Crooks, R., Meldrum, C.J., Thomas, L., Smith, C.J.,
Mowat, D., McPhillips, M. and Spigelman, A.D. (2002) Clin.
Genet. 62, 282^287.
FEBS 27403 12-6-03 Cyaan Magenta Geel Zwart
J. Boudeau et al./FEBS Letters 546 (2003) 159^165164
[63] Resta, N. et al. (1998) Cancer Res. 58, 4799^4801.
[64] Nishioka, Y. et al. (1999) Jpn. J. Cancer Res. 90, 629^632.
[65] Nakagawa, H. et al. (1998) Hum. Genet. 103, 168^172.
[66] Miyaki, M. et al. (2000) Cancer Res. 60, 6311^6313.
[67] Sato, N. et al. (2001) Am. J. Pathol. 159, 2017^2022.
[68] Park, W.S. et al. (1998) Int. J. Oncol. 13, 601^604.
[69] Gruber, S.B. et al. (1998) Cancer Res. 58, 5267^5270.
[70] Su, G.H. et al. (1999) Am. J. Pathol. 154, 1835^1840.
FEBS 27403 12-6-03 Cyaan Magenta Geel Zwart
J. Boudeau et al./FEBS Letters 546 (2003) 159^165 165
